- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07942792
Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit (Diamond)
Evidence-based Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit: an Observational Study
The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).
Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).
Studietyp
Inskrivning (Beräknad)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Consecutive patients referred to the Syncope Unit for severe unexplained syncope
Beskrivning
Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.
Exclusion Criteria: Non-severe syncope Definitions.
-
Unexplained syncope is defined as unexplained etiology or unexplained
-
Severe syncope is defined by the presence of one or more among the following:
-
Suspected life-threatening arrhythmias
-
Substantial impact on patient's quality of life (QoL)
- Frequent episodes
- Restriction of educational or occupational activities (including, but not limited to, unemployment)
- Restriction of social or daily-life activities, e.g. when syncope occurs while driving
-
High risk of clinically significant outcomes
- Syncope associated with major injuries/trauma, i.e. head injury or fractures
- Unpredictable syncope, i.e. without prodrome or identifiable triggers
-
Presence of serious comorbidities, such as concomitant heart disease, neurologic disease, diabetes or renal failure
-
Suspected Autonomic syncope overlapping with suspected psychogenic pseudosyncope
-
-
Non-severe syncope is defined by the presence of one or more among the following:
- Sporadic (isolated) episodes without major impact on patient's QoL
- Predictable syncope, i.e. syncope preceded by prodrome and/or occurring in association with identifiable triggers, with low risk of injuries
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Unexplained syncope
Syncope Unit |
At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.
Tidsram: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway
Tidsram: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Assessment of number and costs of resource utilization associated to the clinical practices
Tidsram: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 09X605
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .